Tang Jia-Liang, Zhou Jian-Kang
Doumeng People's Hospital of Shaoxing, Zhejiang 312071, China.
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2011 Oct;25(5):342-4.
To analyze the mutation patters of HBV P gene and genotyping of heptitis B virus in patients with chronic hepatitis B (CHB) after the emergence of drug-resistance during lamivudine (LAM) therapy.
LAM-resistant mutations and genotype of HBV were dectected in patients with LAM-resistant CHB in our hospital from Sep. 2008 to June. 2010.
107 patients had 8 mutation patterns. YMDD mutations happened in 100%, only YMDD mutation were 43 patients, while others were YMDD combined with rtL180M mutations; the HBV genotype among 107chronic hepatitis was mainly B (25.2%) and C (73.8%) and only 1 patient was happend B and C mixed infection. Genetype C was mainly YMDD combined with rtL180M mutations pattern, the rate is 60.7% (48/79); while genetype B was mainly rtM204 mutation pattern, the rate is 66.7% (18/27); there were significant difference between the genetype B and C in mutation pattern (chi2 = 8.4, 7.2, respectively, P < 0. 01).
YMDD mutation is the major mutation pattern of HBV P gene after emergence of LAM-resistance. Genotypes of hepatitis B virus can determine the related mulation patterns of HBV P gene.
分析拉米夫定（LAM）治疗期间出现耐药的慢性乙型肝炎（CHB）患者乙肝病毒（HBV）P基因的突变模式及基因分型。
对2008年9月至2010年6月我院LAM耐药的CHB患者进行HBV LAM耐药突变及基因分型检测。
107例患者有8种突变模式。YMDD突变发生率为100%，单纯YMDD突变43例，其余为YMDD联合rtL180M突变；107例慢性乙型肝炎患者中HBV基因型主要为B型（25.2%）和C型（73.8%），仅1例为B和C混合型感染。C基因型主要为YMDD联合rtL180M突变模式，发生率为60.7%（48/79）；B基因型主要为rtM204突变模式，发生率为66.7%（18/27）；B和C基因型的突变模式有显著差异（χ2分别为8.4、7.2，P<0.01）。
YMDD突变是LAM耐药后HBV P基因的主要突变模式。乙肝病毒基因型可决定HBV P基因的相关突变模式。
